Unique ID issued by UMIN | UMIN000033590 |
---|---|
Receipt number | R000038308 |
Scientific Title | Effect of JINSHIHOUTOU for patients with Pulmonary Mycobacterium avian complex infection |
Date of disclosure of the study information | 2018/08/01 |
Last modified on | 2018/08/01 17:08:20 |
Effect of JINSHIHOUTOU for patients with Pulmonary Mycobacterium avian complex infection
Effect of JINSHIHOUTOU for MAC patients
Effect of JINSHIHOUTOU for patients with Pulmonary Mycobacterium avian complex infection
Effect of JINSHIHOUTOU for MAC patients
Japan |
pulmonary Mycobacterium avian complex infection
Pneumology |
Others
NO
In MAC patients, we analyze on changes in physical findings with JINSIHOUTOU, and examine the difference between exacerbated patients and non-exacerbated patients.
Efficacy
Not applicable
CAT score, body weight and NK cell activity on administration and 3 months later.
Evaluation of exacerbation factors for exacerbation group and non-exacerbation group
Depression score by SDS, STAI
Chest CT findings
Evaluation of exacerbation factors for exacerbation group and non-exacerbation group
evaluation of safety
Interventional
Single arm
Non-randomized
Open -no one is blinded
Uncontrolled
1
Treatment
Medicine |
JINSHIHOUTOU 9.0g/d (3M~2Y)
20 | years-old | <= |
80 | years-old | > |
Male and Female
1.age between 20 and under 80
2.Gender: male and female
3.Outpatient only
4.Patients satisfying the diagnostic criteria for pulmonary MAC disease)
A.Clinical criteria (satisfy the following two)
1.Chest CT findings indicate nodular shadow or branched shadow, cavitary shadow, bronchiectasis findings.
2.Can exclude other diseases
B.Bacteriological criteria (satisfies one)
1.Culture positive with two or more different sputum
2.Positive cultures in one or more bronchial lavage fluids
3.For transbronchial lung biopsy or lung biopsy tissue, histology findings conformed with pulmonary MAC disease and at the same time tissue or bronchial lavage fluid or sputum one or more culture positive
The above A and B are satisfied.
5. Rifampicin, ethambutol, clarithromycin, streptomycin, kanamycin, rifabutin, sitafloxacin, levofloxacin were not administered more than 14 days.
6. Patients who got informed consent.
1.Rifampicin, ethambutol, clarithromycin, streptomycin, kanamycin, rifabutin, sitafloxacin, levofloxacin are administered
2.Treated for pulmonary tuberculosis
3.With hypokalemia
4.With heart failure
5.With drug hypersensitivity
6.Pregnant and lactating women
7.Patients who participated in other clinical trials within 4 months
8.In addition, patients who are judged inappropriate.
30
1st name | |
Middle name | |
Last name | Yuko Waseda |
Faculty of Medical Sciences University of Fukui
Third Department of Internal Medicine
23-3 Matsuoka Shimoaizuki, Eiheiji, Yoshida-gun, Fukui
0776-61-8355
yuwaseda@gmail.com
1st name | |
Middle name | |
Last name | Yuko Waseda |
Faculty of Medical Sciences University of Fukui
Third Department of Internal Medicine
23-3 Matsuoka Shimoaizuki, Eiheiji, Yoshida-gun, Fukui
0776-61-8355
yuwaseda@mgmail.com
Faculty of Medical Sciences University of Fukui
aculty of Medical Sciences University of Fukui
Self funding
NO
福井大学医学部附属病院
2018 | Year | 08 | Month | 01 | Day |
Unpublished
Open public recruiting
2018 | Year | 03 | Month | 01 | Day |
2018 | Year | 03 | Month | 01 | Day |
2021 | Year | 01 | Month | 31 | Day |
2018 | Year | 08 | Month | 01 | Day |
2018 | Year | 08 | Month | 01 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000038308